1. Home
  2. CURV vs MDXH Comparison

CURV vs MDXH Comparison

Compare CURV & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Torrid Holdings Inc.

CURV

Torrid Holdings Inc.

HOLD

Current Price

$1.12

Market Cap

185.4M

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.60

Market Cap

203.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CURV
MDXH
Founded
2001
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
185.4M
203.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CURV
MDXH
Price
$1.12
$3.60
Analyst Decision
Hold
Strong Buy
Analyst Count
6
3
Target Price
$1.59
$7.67
AVG Volume (30 Days)
406.5K
191.1K
Earning Date
12-03-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,486,000.00
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
N/A
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.68
52 Week Low
$1.08
$1.35
52 Week High
$7.19
$5.33

Technical Indicators

Market Signals
Indicator
CURV
MDXH
Relative Strength Index (RSI) 40.94 42.64
Support Level $1.08 $3.40
Resistance Level $1.46 $3.74
Average True Range (ATR) 0.10 0.23
MACD 0.01 0.02
Stochastic Oscillator 10.67 81.43

Price Performance

Historical Comparison
CURV
MDXH

About CURV Torrid Holdings Inc.

Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: